Chronic Pain: The Need and Hope for Opioid Alternatives  by unknown
EBioMedicine 5 (2016) 1
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comEditorialChronic Pain: The Need and Hope for Opioid AlternativesOn January 11, 2016, a Phase 1 trial in France of the investigational
drug BIA 10-2474was abruptly haltedwhen one of the six dosed subjects
fell into a coma after experiencing symptoms resembling a stroke. The
subject died several days later and four otherswere leftwithwhat doctors
suspect may be lasting neurological damage. What precipitated this trag-
edy is still unclear. As an inhibitor of fatty acid amide hydrolase, a critical
enzyme in the biosynthesis of endocannabinoids, it was thought that BIA
10-2474 could target aberrant neurotransmission in disorders ranging
from anxiety and Parkinson's disease to chronic pain. While the failure
of the BIA 10-2474 trial should not be downplayed, it does at least herald
the critical need for further investigation into new ways of treating ner-
vous system disorders— including chronic pain, whose current therapies
include those that may themselves be perilous.
Chronic pain is generally deﬁned as that which lasts between three
and six months after the acute symptoms should have subsided. It can
arise from myriad conditions including arthritis, diabetic neuropathy,
cancer, traumatic injury, certain viral infections, and many other dis-
eases that lead to persistent inﬂammation or nerve dysfunction. Rough-
ly 25% of people worldwide will at some point suffer from chronic pain.
Consequently, theWHO estimates chronic pain to be one of the leading
causes of Years Lost to Disability globally. In the US alone, where up to
12 million people have chronic pain, this equates to an economic bur-
den of nearly $635 billion per year.
Opioids are widely used as ﬁrst line drugs for both acute and chronic
moderate to severe pain.While opioids often produce unmatched anal-
gesic effects, at sufﬁcient doses or with prolonged use they can trigger
psychoactive effects, tolerance, and addiction. Prescription opioid
abuse has exploded in developed nations over the last decade. In the
US, the epidemic has grown to such proportions that the Centers forDis-
ease Control estimates over 19,000 people died from overdose of pre-
scription opioids in 2014, a cause of death whose rate now exceeds
that of motor vehicle accidents. These troubling statistics led the US
Food and Drug Administration in February, 2016 to largely amend its
stance on opioids. Among other policy statements was a call to action
to develop novel therapies with reduced potential for misuse.
Given that opioids are the only currently-available means of relief
from chronic pain for many patients, one branch of research focusses
on ways to limit their use at the high doses necessary to elicit harmful
effects. These efforts include drug formulations that confer delayed re-
lease and technologies such as implantable devices that dispense pre-
cise doses to provide only analgesia. Other research is aimed at
developing opioids with fewer adverse effects. Of the mu, delta, and
kappa subtypes of opioid receptors, most analgesia is thought to derive
from mu activation. Recent studies in pre-clinical pain models suggest
that a synthetic opioid derivative, UMB 425, which both agonizes mu
and antagonizes delta receptors, provides analgesia without the devel-
opment of tolerance. Another compound, MMG22, both agonizes mu
receptors for analgesia and antagonizes metabotropic glutamatehttp://dx.doi.org/10.1016/j.ebiom.2016.03.011
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veloping molecules with selective binding afﬁnities for different opioid
receptor subtypes to reduce the risk of dependence and overdose, in-
cluding themu-biased agonist oliceridine that recently won FDA Break-
through Drug approval and is in Phase 3 development.
Basic neuroscience ﬁndings on pain have led to targets not related to
opioid receptor modulation. The γ-aminobutyric acid (GABA) receptor
agonists gabapentin and pregabalin have been approved for various
chronic pain syndromes for several years, as have the serotonin-
norepinephrine reuptake inhibitors (SNRIs) duloxetine andminacipran.
In the pre-clinical pipeline, researchers are exploring a range of ion
channels, receptors, and pathways to modulate pain. Sodium and calci-
um channels that are selectively expressed in sensory neurons are an at-
tractive target as they could provide analgesia similar to traditional
anesthetics without central depressant effects. Compounds that block
capsaicin receptors and transient receptor potential (TRP) channels on
nociceptive neurons or purinergic and TLR4 receptors on glial cells
have also been shown to confer analgesia. An angiotensin Type II recep-
tor antagonist, EMA401, recently showed efﬁcacy in a Phase 2 trial for
post-herpetic neuralgia. Several groups are also investigating anti-
nerve growth factor (NGF) antibodies, with clinical trials underway
using tanezumab for the treatment of osteoarthritis and cancer pain.
Cannabis can be an effective treatment for some chronic pain suf-
ferers and is available by prescription for in some jurisdictions. As
with opioids, though, there are concerns about the psychoactive effects
of cannabis and its potential for misuse. Therefore, synthetic molecules
that selectively interact with only therapeutic targets are being investi-
gated. Among them, the cannabinoid-derivatives nabilone and
dronabinol are approved in many regions as adjunctive treatments for
certain chronic pain conditions. Modulators of the body's biosynthetic
pathways of endocannabinoids — including inhibitors of fatty acid
amide hydrolase like BIA 10-2474 — are being explored by many
groups. Despite the recent tragedy related to BIA 10-2474, the
endocannabinoid system is still a promising pain target.
Many questions remain unanswered about the BIA 10-2474 trial in
France. With the investigation still ongoing it would be irresponsible
to speculate on the speciﬁcs of this trial's failure. Along with ensuring
trials are designed and conducted with patient safety at the fore, we
must also remain diligent in weighing the rewards and risks of translat-
ing pre-clinical ﬁndings to the clinic. Currently, with opioids the stan-
dard of care for pain management, doctors and patients must weigh
the rewards and risks of such treatment: analgesia versus potentialmis-
use. Viable alternatives to opioids remain a much-needed reward for
sufferers of chronic pain.
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